Genmab A/S reported revenue of $2,051 million for the first six months of 2026, a 25% increase from $1,640 million in the same period of 2025, according to the company's interim report released August 6.

The revenue growth was driven primarily by higher royalties from DARZALEX and Kesimpta, as well as increased net product sales of EPKINLY. Royalty revenue rose 24% to $1,708 million. Net sales of DARZALEX by Johnson & Johnson reached $8,171 million in the first half of 2026, up 21% from $6,776 million a year earlier. Global net sales of EPKINLY/TEPKINLY grew 48% to $312 million.

Operating profit was $555 million in the first half of 2026, compared with $548 million in the same period of 2025. Adjusted operating profit, which excludes acquisition and integration-related charges and amortization of acquired intangible assets, rose to $656 million from $554 million. Adjusted operating expenses increased 28% to $1,270 million, reflecting pipeline investment and commercialization preparations.

Genmab also announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma, with the trial showing a statistically significant improvement in progression-free survival.

The company updated its full-year 2026 financial guidance, raising its revenue outlook to a range of $4,325 million to $4,525 million, with a midpoint of $4,425 million, compared with a prior midpoint of $4,230 million. Adjusted operating profit guidance was revised to a range of $1,065 million to $1,385 million, with a midpoint of $1,225 million, up from a prior midpoint of $1,150 million.

The updated guidance reflects higher expected royalty revenues from DARZALEX and net sales of EPKINLY. Genmab is listed on Nasdaq Copenhagen under the ticker GMAB and on Nasdaq in the United States.